Phase III Placebocontrolled, Randomized Clinical Trial with Synthetic Crohn's Disease Patients to Evaluate Treatment Response

Emerging Trends in Applications and Infrastructures for Computational Biology, Bioinformatics, and Systems Biology: Systems and Applications

Volumn , Issue , 2016, Pages 411-427

  Abedi, V ^a   Lu, P ^a   Hontecillas, R ^a   Verma, M ^a   Vess, G A ^a   Philipson, C W ^b   Carbo, A ^b   Leber, A ^a   Juni, N T ^a   Hoops, S ^a   Bassaganya Riera, J ^a  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

^b BIOTHERAPEUTICS INC   (United States)

Author keywords

Crohn's disease; IFN ; In silico clinical trial; LANCL2; Machine learning; Mucosal immunity; SMAD7; Synthetic population; TNF ; Virtual patient

Indexed keywords

ARTIFICIAL INTELLIGENCE; DRUG PRODUCTS; FATTY ACIDS; LEARNING SYSTEMS; LINOLEIC ACID; PATIENT TREATMENT; SUPERVISED LEARNING;

CLINICAL TRIAL; CROHN'S DISEASE; LANCL2; MUCOSAL IMMUNITY; SMAD7; SYNTHETIC POPULATIONS; VIRTUAL PATIENTS;

DISEASES;

EID: 84969610554     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-804203-8.00028-6     Document Type: Chapter

References (44)

1. Molodecky NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1):46-54.e42. quiz e30.
2. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012;380(9853):1590-605.
3. Barrett JC, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40(8):955-62.
4. Papadakis KA. Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep 2004;4(1):83-9.
5. Marks DJ. Defective innate immunity in inflammatory bowel disease: a Crohn's disease exclusivity? Curr Opin Gastroenterol 2011;27(4):328-34.
6. Lawrance IC, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumornecrosis- factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol 2010;25(11):1732-8.
7. Khan KJ, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106(4):630-42.
8. Auer K, et al. Translational research and efficacy of biologics in Crohn's disease: a cautionary tale. Expert Rev Clin Immunol 2014;10(2):219-29.
9. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012;61 (6):918-32.
10. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136(4):1182-97.
11. Bassaganya-Riera J, et al. Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease. Clin Nutr 2012;31(5):721-7.
12. Romero K, et al. The future is now: model-based clinical trial design for Alzheimer's disease. Clin Pharmacol Ther 2015;97(3):210-4.
13. Brown D, et al. Trauma in silico: individual-specific mathematical models and virtual clinical populations. Sci Transl Med 2015;7(285):285ra61.
14. Buczak AL, Babin S, Moniz L. Data-driven approach for creating synthetic electronic medical records. BMC Med Inform Decis Mak 2010;10:59.
15. Eekhout I, et al. Missing data: a systematic review of how they are reported and handled. Epidemiology 2012;23(5):729-32.
16. Wendelsdorf K, et al. Model of colonic inflammation: immune modulatory mechanisms in inflammatory bowel disease. J Theor Biol 2010;264(4):1225-39.
17. Carbo A, et al. Systems modeling of molecular mechanisms controlling cytokine-driven CD4+ T cell differentiation and phenotype plasticity. PLoS Comput Biol 2013;9(4):e1003027.
18. Carbo A, et al. Computational modeling of heterogeneity and function of CD4+ T cells. Front Cell Dev Biol 2014;2:31.
19. Lu P, et al. Supervised learning methods in modeling of CD4+ T cell heterogeneity. BioData Min 2015;8:27.
20. Lu P, et al. Supervised learning with artificial neural network in modeling of cell differentiation process. In: Tran QN, Arabnia H, editors. Emerging trends in computational biology, bioinformatics, and systems biology. Waltham, MA: Elsevier; 2015. p. 674.
21. Clermont G, et al. In silico design of clinical trials: a method coming of age. Crit Care Med 2004;32 (10):2061-70.
22. Monteleone G, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med 2015;372(12):1104-13.
23. Lu P, et al. Lanthionine synthetase component C-like protein 2: a new drug target for inflammatory diseases and diabetes. Curr Drug Targets 2014;15(6):565-72.
24. Magnone M, et al. Autocrine abscisic acid plays a key role in quartz-induced macrophage activation. FASEB J 2012;26(3):1261-71.
25. Carbo A, Hontecillas R, Cooper J, Gandour R, Ehrich M, Bassaganya-Riera J. Lanthionine synthetase C-like receptor 2 (LANCL2): a novel therapeutic target for inflammatory bowel disease. Gastroenterology 2015;148 (4):S686-7.
26. Plevy SE, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997;159(12):6276-82.
27. Nakao A, et al. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature 1997;389 (6651):631-5.
28. Monteleone G, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther 2012;20(4):870-6.
29. Magnone M, et al. Microgram amounts of abscisic acid in fruit extracts improve glucose tolerance and reduce insulinemia in rats and in humans. FASEB J 2015;29(12):4783-93.
30. Sandborn WJ, et al. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011;9(8):670-678.e3.
31. Günther F, Fritsch S. neuralnet: training of neural networks. R J 2010;2(1):30-8.
32. Liaw A, Wiener M. Classification and regression by randomForest. R News 2002;2(3):18-22.
33. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104(2):465-83.
34. Khanna R, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther 2015;41(1):77-86.
35. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12(8):1246-1256.e6.
36. Boirivant M, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-β1-mediated suppression of colitis. Gastroenterology 2006;131(6):1786-98.
37. Bassaganya-Riera J, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 2004;127(3):777-91.
38. Bassaganya-Riera J, Hontecillas R. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin Nutr 2006;25(3):454-65.
39. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997;113(2):383-9.
40. Nielsen OH. New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne) 2014;1:3.
41. Colagiuri B, et al. The placebo effect: from concepts to genes. Neuroscience 2015;307:171-90.
42. Abedi V, et al. ENISI multiscale modeling of mucosal immune responses driven by high performance computing, In: IEEE international conference on bioinformatics and biomedicine (BIBM), Washington, DC; 2015. p. 680-4.
43. Mei Y, et al. Multiscale modeling of mucosal immune responses. BMC Bioinform 2015;16(Suppl. 12):S2.
44. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001;108(4):601-9.